Next 10 |
2024-04-29 13:26:57 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony inks licensing deal for sleep disorder therapy Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line ...
2024-04-29 11:15:34 ET Major earnings expected before the bell on Tuesday include: Enterprise Products Partners ( EPD ) The Coca-Cola ( KO ) McDonald's ( MCD ) 3M Company ( MMM ) PayPal Holdings ( PYPL ) Read the full article on Seeking Alph...
2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 f...
2024-04-11 12:36:36 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line Harmony Biosciences Q4 2023 Earnings Preview Se...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PR Newswire ...
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE PR Newswire PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will parti...
2024-03-18 14:07:39 ET Summary The healthcare sector is overvalued by about 13% relative to 11-year averages, but overvaluation varies a lot across subsectors. Healthcare equipment has the worst value and quality scores. iShares Global Healthcare ETF is a global alternative to...
2024-03-02 14:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 f...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PR Newswire ...